By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer said after the close of the market Tuesday that it has reached an agreement to sell its Illumination and Detection Solutions business to private equity group Veritas Capital Fund III for around $500 million in cash.

PerkinElmer said that the divestiture would enable it to reinvest in its core Human Health and Environmental Health businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.